Clinical Trial Update: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating lenalidomide with or without epoetin alfa for myelodysplastic syndrome and associated anemia, with results posted in July 2021…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anemia, Chronic Myelomonocytic Leukemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-07-08